Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ...
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...
Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin ...
Traders use this information to analyze potential trades and assess market sentiment for Oruka Therapeutics. In The Money Expiration Date December 20, 2024 March 21, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback